![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 12, 10315-10322, March 22, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
,
,
,
,
,
,
,
¶
From the
Department of Molecular Medicine, Osaka
University Graduate School of Medicine, and the § Department
of Medical Science I, School of Health and Sport Science, Osaka
University, Yamada-oka 2-2, Suita, Osaka 565-0871, Japan
Received for publication, November 20, 2001
| |
ABSTRACT |
|---|
|
|
|---|
Hepatoma-derived growth factor (HDGF) is the
original member of the HDGF family of proteins, which contains a
well-conserved N-terminal amino acid sequence (homologous
to the amino terminus of HDGF;
hath) and nuclear localization signals (NLSs) in gene-specific regions other than the hath region. In addition to a bipartite NLS in a
gene-specific region, an NLS-like sequence is also found in the hath
region. In cells expressing green fluorescence protein (GFP)-HDGF,
green fluorescence was observed in the nucleus, whereas it was detected
in the cytoplasm of cells expressing GFP-HDGF with both NLSs mutated or
deleted. GFP-hath protein (GFP-HATH) was distributed mainly in the
nucleus, although some was present in the cytoplasm, whereas GFP-HDGF
with a deleted hath region (HDGFnonHATH) was found only in the nucleus.
Exogenously supplied GFP-HDGF was internalized and translocated to the
nucleus. GFP-HATH was internalized, whereas GFP-HDGFnonHATH was not.
Overexpression of HDGF stimulated DNA synthesis and cellular
proliferation, although HDGF with both NLSs deleted did not.
Overexpression of HDGFnonHATH caused a significant stimulation of DNA
synthesis, whereas that of hath protein did not. HDGF containing the
NLS sequence of p53 instead of the bipartite NLS did not stimulate DNA
synthesis, and truncated forms without the C- or N-terminal side of
NLS2 did not. These findings suggest that the gene-specific region, at
least the bipartite NLS sequence and the N- and C-terminal neighboring
portions, is essential for the mitogenic activity of HDGF after nuclear translocation.
Hepatoma-derived growth factor
(HDGF)1 is the first member
of the HDGF family of proteins that contain a well-conserved N-terminal amino acid sequence which we call the hath (homologous to
amino terminus of HDGF) region (1,
2). HDGF was purified from the conditioned medium of human
hepatoma-derived HuH-7 cells, which proliferate autonomously in a
serum-free chemically defined medium, and its complementary DNA was
cloned from a HuH-7 cell cDNA library (1, 3). HDGF has
growth-stimulating activity in fibroblasts, hepatoma cells, vascular
smooth muscle cells, and endothelial cells (1, 3-5). Its deduced amino
acid sequence demonstrated that it lacked a signal peptide-like
hydrophobic sequence essential for classic secretion. However, the
conditioned medium of COS7 cells transfected with cDNA expressing
copious amounts of human HDGF showed growth-stimulating activity (1, 4). Furthermore, HDGF family proteins have a basic motif homologous to
the reported consensus sequences for bipartite nuclear localization signals (NLSs) in gene-specific amino acid sequences other than the
hath region of the molecule (1, 2, 6, 7). Additionally, an NLS-like
basic amino acid-rich region is found in the hath region. Indeed, one
of the HDGF family proteins, HDGF-related protein (HRP)-1 is detected
immunohistochemically in the nucleus of germ cells, and another member,
HRP-3, can translocate to the nucleus of its target cells (6, 7).
Recently, HDGF was detected in the nucleus using anti-C terminus HDGF
antibody and found to co-localize with the proliferating cell nuclear
antigen in vascular smooth muscle cells (5). Among the growth factors,
cytokines, and hormones identified previously, the following
polypeptide factors have been reported to contain one or more NLSs and
to undergo nuclear translocation for mitogenesis: acidic or basic fibroblast growth factor (FGF), FGF-3, schwannoma-derived growth factor
(SDGF), ciliary neurotrophic factor, amphiregulin, angiogenin, and lens
epithelium-derived growth factor (LEDGF) (8-23). These findings
prompted us to study whether HDGF translocates to the nucleus via these
NLSs, and whether its nuclear translocation is essential for induction
of cell growth activity.
In this study, we investigate the functional roles of the putative NLSs
by use of PCR-directed mutagenesis and the relationship between its
nuclear translocation ability and growth-stimulating activity in the
HDGF molecule. Furthermore, we analyze which part of the HDGF molecule
is essential for internalization and the mitogenic activity.
Plasmid Construction of Truncated and Mutant Forms of
HDGF--
We have named an NLS-like basic amino acid-rich region in
the hath region and the basic region homologous to a bipartite NLS in a
gene-specific part as NLS1 and NLS2, respectively. We constructed chimera proteins of wild HDGF or 12 truncated or mutant forms. The
truncated or mutant forms of HDGF were named as follows: hath region
from Ser2 to Ser98 (HATH), HDGF with
deleted hath region (HDGFnonHATH), truncated form consisting of peptide
from Ser2 to Lys170 (HDGF-LA), truncated form
consisting of peptide from Ser2 to Leu154
(HDGF-SA), truncated form consisting of peptide from Lys155
to C-terminal Leu240 (HDGF-LP), truncated form
consisting of peptide from Glu171 to C-terminal
Leu240 (HDGF-SP), NLS1-mutated HDGF (HDGFmN1), NLS2-mutated
HDGF (HDGFmN2), both NLS1- and NLS2-mutated HDGF (HDGFmN1mN2), both
NLS1- and NLS2-deleted HDGF (HDGFdN1dN2), hath region with mutated NLS1 (HATHmN1), and hath region with deleted NLS1 (HATHdN1) (see Fig. 1 below).
First, we constructed four mutants of two putative NLSs in the HDGF
molecule. The four HDGF mutants were HDGFmN1, HDGFmN2, HDGF with
deleted NLS1 (HDGFdN1), and HDGF with deleted NLS2 (HDGFdN2). Deletions
and mutations were introduced into the putative NLSs of human HDGF by
PCR-directed mutagenesis. PCR was performed using appropriate synthetic
oligonucleotides as primers and full-length HDGF cDNA as template.
The point mutations introduced into NLS1 were Lys75
(AAG) to Asn (AAC), Lys78 (AAG) to Asn (AAT),
Arg79 (AGG) to Gln (CAG), and Lys80 (AAA) to
Asn (AAT). A BstEII site was created by changing the codon
of Gly74 from GGC to GGT and used to make a PCR-generated
fragment spanning the mutated NLS1. The same strategy was used in the
construction of NLS2 point mutations. The amino acid changes were
Lys155 (AAG) to Asn (AAT), Arg156 (AGG) to Gln
(CAG), Arg157 (AGA) to Gln (CAA), Lys167 (AAA)
to Asn (AAT), and Lys170 (AAG) to Asn (AAT). A
XbaI site was introduced by changing the codons of
Leu161 from TTG to CTT and Leu162 from CTG to
CTA. The junction point of the in-frame deletion mutants of NLS1 was
made using an NruI linker, which made a change of
Gly79 (GGG) to Ala (GCC). Deletion mutants of NLS1 also
include an XhoI restriction site at the junction point with
no amino acid substitution. Briefly, for HDGFdN1, two PCR
products were amplified using HF-S1 and dN1-S, described below as sense
primers, and dN1-R and HF-R1 as antisense primers, which contained only
sequences upstream of NLS1 and downstream of NLS1, were ligated at the
NarI site. For HDGFmN1, two PCR products were amplified
using HF-S1 and mN1-S, described below as sense primers, and mN1-R and
HF-R1 as antisense primers, which contained NLS1 with mutations K75N, K78N, R79Q, and K80N, were ligated at the BstEII site. These
HDGF cDNAs were inserted into the SpeI and
XbaI sites of pBluescript II vectors. The cDNA for
HDGFdN2 was constructed by ligation at the XhoI site after
amplification by PCR using HF-S2 and dN2-S as sense primers, and dN2-R
and HF-R2 as antisense primers. For HDGFmN2, two PCR products
were amplified using HF-S2 and mN2-S as sense primers and mN2-R and
HF-R2 as antisense primers, which contained an upstream sequence of
NLS2 with mutations K155N, R156Q, and R157Q, and the downstream
sequence of NLS2, with mutations K167N and K170N, was ligated at the
XbaI site. The cDNA for HDGFdN1dN2 and HDGFmN1mN2 was
constructed after amplification by PCR using HDGFdN1 and HDGFmN1
cDNA as templates, respectively, as described above for HDGFdN2 and
HDGFmN2. These cDNAs were inserted into the HindIII and
SpeI sites of the pRc/RSV vector. The sequences of
primers were as follows: HF-S1, 5'-GCACTAGTCGATCCAACCGGCAGAAGGA-3'; dN1-R, 5'-AATGGCGCCAAACTTCTCCTTGGATT-3'; dN1-S,
5'-AATGGCGCCTTCAGCGAGGGGCTGTGGGA-3'; HF-R1,
5'-GCTCTAGACAGGCTCTCATGATCTCTGA-3'; mN1-R,
5'-GGGCTTGCCAAACTTCTCCTTGGATTC-3'; mN1-S,
5'-TTTGGTAACCCCAACAATCAGAATGGGTTCAGCGAGGGGC-3'; HF-S2, 5'-GCAAGCTTAGCCCCGCCATGTCGCGATC-3'; dN2-R,
5'-CGCTCGAGCGCTCCTTTCTCGTTCTTCTCCTT-3'; dN2-S,
5'-CGCTCGAGGCAGAAAACCCTGAAGGAGAG-3'; HF-R2,
5'-GCACTAGTCAGGCTCTCATGATCTCTGA-3'; mN2-R,
5'-CCTCTAGAAAGTCCCCTGCTTGCTGATTCAACGCTCCTTT-3'; and mN2-S, 5'-GCTCTAGAGGACTCTCCTAATCGTCCCAATGAGGC-3'.
For construction of green fluorescence protein (GFP)-chimera proteins,
we amplified the wild HDGF and its six truncated forms by PCR using
appropriate synthetic oligonucleotides as primers and full-length HDGF
cDNA as template (Fig. 1).
Furthermore, six mutant forms of HDGF were amplified by PCR using
appropriate synthetic oligonucleotides as primers and the corresponding
HDGF mutant cDNA as template. Primer 1, 5'-GCCCCAGATCTTCGCGATCCAACCGGCAGAAGGAG-3'; primer 2, 5'-AACATGTCGACCAGGCTCTCATGATCTCTGATGCC-3'; primer 3, 5'-AGTCAGTCGACGGAAGCCTTGACAGTAGGGTTGTTC-3'; primer 4, 5'-ACGTTGTCGACCTACTTGGGACGTTTAGGAGAGTCCTC-3'; primer 5, 5'-CCTGCGTCGACCTACAACGCTCCTTTCTCGTTCTTCTC-3'; primer 6, 5'-AAGGAAGATCTAAGAGGAGAGCAGGGGACTTGCTG-3'; primer 7, 5'-AACGTAGATCTGAGGCAGAAAACCCTGAAGGAGAG-3'; primer 8, 5'-TCAAGAGATCTGGCTATCAGTCCTCCCAGAAAAAGA-3'; primer 9, 5'-ACGAGAGATCTAAGGAGAAGTTTGGC-3'; and primer 10, 5'-CACAGGTCGACTCAGAACCCTTTCCTCTT-3'. For GFP-wHDGF and its mutant
forms, including GFP-HDGFmN1, GFP-HDGFmN2, GFP-HDGFmN1mN2, and
GFP-HDGFdN1dN2, primer 1 was used as the sense primer and primer 2 as
the antisense primer. For GFP-HATH, GFP-HATHmN1, and GFP-HATHdN1,
primers 1 and 3 were used as the sense and antisense primers,
respectively. For GFP-HDGFnonHATH, primers 8 and 2 were used. For
GFP-HDGF-LA and GFP-HDGF-SA, primer 1 was used as the sense primer and
primers 4 and 5 were used as the antisense primers. For GFP-HDGF-LP and
GFP-HDGF-SP, primer 2 was used as the antisense primer and primers 6 and 7 were used as the sense primers. For GFP-NLS1 (GFP fusion peptide
consisting of 13 amino acids (Lys70 through
Phe82) including NLS1), primers 9 and 10 were used as the
sense and antisense primers, respectively. For GFP-NLS2 (GFP-NLS2
peptide (Lys155 through Lys170)), primers 4 and
6 were used as the antisense and sense primers, respectively. These 15 amplified cDNAs were inserted into the BglII and
SalI sites of pEGFP-C1 vector
(CLONTECH).
We constructed a mutant form of HDGF containing the NLS sequence of p53
(Lys305 through Lys321) instead of NLS2
(GFP-HDGF-p53NLS). The cDNA for the NLS of p53 was amplified
by PCR using appropriate synthetic oligonucleotides: 5'-ATACGCTCGAGAAGCGAGCACTGCCCAACA-3' as the sense primer and
5'-TACGTCTCGAGTTTCTTCTTTGGCTGGGGA-3' as the antisense primer, and
5'-CTCGAGAAGCGAGCACTGCCCAACAACACCAGCTCCTCTCCCCAGCCAAAGAAGAAACTCGAG-3' corresponding to the NLS sequence of p53 as a template (24). The
amplified cDNA was inserted into the XhoI site of
HDGFdN1dN2 cDNA in pEGFP-C1.
We constructed myc-tagged proteins of wild HDGF and HDGFdN1dN2 for
stable transformants. We amplified these cDNAs by PCR using 5'-GAGCCGGATCCGCTCGCGATCCAACCGGCAGAAGG-3' as the sense primer and
5'-AACATTCTAGACTACAGGCTCTCATGATCTCTGATG-3' as the antisense primer and the cDNA of HDGF and HDGFdN1dN2 as templates for myc-wHDGF and myc-HDGFdN1dN2, respectively. These amplified cDNAs were
inserted into the BamHI and XbaI sites of the
pEF-BOS vector (25). All PCR products were analyzed by restriction
mapping and dideoxynucleotide sequencing.
Gene Transfection--
A human renal epithelial cell line (293 cells), a human hepatoblastoma cell line (HepG2 cells), and NIH3T3
cells were cultured in Dulbecco's modified Eagle's medium
(DMEM) supplemented with 10% FCS and antibiotics. Using a
Mammalian transfection kit (Stratagene), 293 cells were transiently
transfected with 6 µg of pEGFP-C1 containing cDNA of wild type or
mutant forms of HDGF. HepG2 cells and NIH3T3 cells were co-transfected
with 18 µg of pEF-BOS containing myc-tagged proteins and 2 µg of
pST vector with the neomycin-resistance gene. Transfected cells were
cultured in DMEM with 10% FCS in 3% CO2 at
37 °C, and 24 h later the DMEM was replaced with
fresh medium and cultured for 3 days in 5% CO2 at
37 °C. After cultivation with 0.9 mg/ml neomycin for about 1 month,
stable transformants of HepG2 cells and NIH3T3 cells were selected and cloned.
Visualization of GFP-chimera Proteins--
Living 293 cells
transfected with pEGFP-C1 were evaluated on days 1, 2, 3, or 4 using
confocal microscopy equipped for GFP visualization (488-nm excitation
and FITC filter set). The conditioned media of 293 cells expressing
GFP-chimera proteins were concentrated about 20-fold with Centricon 10 (Amicon) and then supplied to parent 293 cells. GFP-HDGF was examined
after being purified from the conditioned medium of 293 cells
expressing GFP-HDGF by heparin-Sepharose column chromatography, too.
Three days later, we evaluated the intracellular fluorescence of these
cells by confocal microscopy equipped for GFP visualization.
DNA Synthesis and Cell Proliferation Assay--
For the DNA
synthesis assay, HepG2 cells and NIH3T3 cells expressing myc-tagged
proteins were plated onto 96-well plates at a density of 2 × 103 cells/well in DMEM supplemented with 10%
FCS. Twenty-four hours later, HepG2 cells and NIH3T3 cells were given
fresh medium supplemented with 1% and 5% FCS, respectively. 2 or 4 days later, these cells were harvested, and [3H]thymidine
(Thd) incorporation into DNA was measured. 293 cells expressing
GFP-chimera proteins were plated onto 96-well plates at a density of
1 × 103 cells/well in DMEM supplemented
with10% FCS. Twenty-four hours later, these cells were given fresh
medium supplemented with 1% FCS, and the cells were harvested 4 days later.
For cell proliferation assay, HepG2 cells expressing myc-tagged
proteins were plated onto 96-well plates at a density of 3 × 103 cells/well in DMEM supplemented with 10%
FCS. After 24 h, HepG2 cells were given fresh medium supplemented
with 10% FCS. Cell numbers were measured 2 and 4 days later using MTS
colorimetric assay (Promega, Madison).
Western Blot Analysis--
HepG2 cells and NIH3T3 cells
expressing myc-tagged proteins were cultured in 6-well plates to
semiconfluence. Then cells were collected in 1.5-ml tubes and washed
twice with phosphate-buffered saline. They were resuspended with 50 µl of 2× sample buffer (containing 0.5 M
Tris(hydroxymethyl)aminomethane hydrochloride (pH 6.8), 10% SDS, 20%
glycerol, and 0.01% bromphenol blue) and boiled at 99.9 °C for 5 min. After SDS-PAGE, each sample was transferred to an Immobilon
membrane (Millipore, Bedford, TX). To detect myc-tagged proteins,
membranes were incubated with anti-c-Myc monoclonal antibody (Ab-1
monoclonal) (Calbiochem, Cambridge, UK) and visualized with horseradish
peroxidase-linked anti-mouse IgG using the enhanced chemiluminescence
(ECL) system (Amersham Biosciences, Inc., UK). For detection of HDGF,
we used rabbit polyclonal anti-C terminus human HDGF IgG and visualized
the samples with horseradish peroxidase-linked anti-rabbit IgG
using the ECL system.
HDGF Translocates to the Nucleus in Living Cells via Nuclear
Localization Signals--
HDGF contains a basic motif,
155KRRAGLLEDSPKRPK170
(basic residues underlined) homologous to the consensus sequences of
bipartite NLS (NLS2), in a gene-specific area other than the hath
region that consists of two clusters of basic residues separated by
10-12 amino acids, including proline residues (26, 27). Additionally, another NLS-like basic amino acid-rich region,
75KPNKRK80 (basic
residues underlined) (NLS1), was found in the hath region (29). To
clarify whether HDGF can translocate to the nucleus and which NLS is
the functional sequence in the HDGF molecule, 293 cells were
transfected with an expression vector encoding a GFP-tagged human HDGF
cDNA and mutant HDGF cDNAs. As shown in Fig.
2, transfected cells expressing GFP-wHDGF
showed green fluorescence only in the nucleus; however, cells
expressing GFP-HDGFdN1dN2 or GFP-HDGFmN1mN2 showed fluorescence in the
cytoplasm, not in the nucleus. In the transfected cells expressing
GFP-HDGFmN2 or the truncated form without NLS2 (GFP-HDGF-SA), green
fluorescence was detected in the nucleus, with some amount also found
in the cytoplasm. HDGFmN1 translocated to the nucleus, as did the
truncated forms with NLS2 (HDGF-LP and HDGFnonHATH), and neither was
found in the cytoplasm. Most of the hath proteins with an intact NLS1 were transported to the nucleus, but variable amounts of hath protein
remained in the cytoplasm. HATHmN1 and HATHdN1 remained in the
cytoplasm. On the other hand, only NLS2 peptide could translocate green
fluorescence protein to the nucleus. Most of the GFP-NLS1 was
transported to the nucleus, showing a similar pattern of fluorescence to hath protein. NLS1 also has nuclear translocational potential, but
its activity is weaker than that of NLS2. The two NLSs can together
undoubtedly translocate HDGF protein to the nucleus.
Exogenously Added GFP-HDGF Is Internalized and Accumulated in the
Nucleus--
Exogenous HDGF stimulated the growth of fibroblasts and
endothelial cells, vascular smooth muscle cells, and some hepatoma cells. We investigated whether exogenously added GFP-HDGF was transported to the nucleus. After the addition of the concentrated conditioned medium of GFP-wHDGF, GFP-HDGFdN1dN2, GFP-HATH, or GFP-HDGFnonHATH-expressing cells, 293 cells were observed 24, 48, 72, and 96 h later by fluorescence detection. The purified fraction of
GFP-wHDGF protein from the conditioned medium of 293 cells expressing
GFP-wHDGF was examined also (data not shown). In 293 cells given
GFP-wHDGF extracellularly, green fluorescence in the nucleus was
observed from 72 h (Fig. 3). Nuclear
fluorescence was also observed at 72 h in NIH3T3 cells given
GFP-wHDGF. Whereas, green fluorescence was observed only in the
cytoplasm, not nucleus, in 293 cells given GFP-HDGFdN1dN2.
Interestingly, in cells treated with GFP-HATH extracellularly, green
fluorescence was observed in both the cytoplasm and nucleus, similar to
GFP-HATH-expressing cells. Exogenously supplied wild HDGF, HDGFdN1dN2,
and hath protein show similar patterns of intracellular localization to
their overexpressing cells. On the other hand, green fluorescence was
not observed in wild 293 cells given GFP-HDGFnonHATH and GFP-HDGF-LP
extracellularly, suggesting that HDGF protein with a deleted hath
region could not be internalized into the cells.
Nuclear Translocation of HDGF Is Essential for Its
Growth-stimulating Activity--
We investigated the role of nuclear
translocation in the cell growth activity of HDGF. Because the effect
of HDGF on cell proliferation is more prominent in cells overexpressing
HDGF, we investigated the cell growth activity of truncated or mutant forms of HDGF by use of overexpressing cells. HDGF stimulated the
growth of some hepatoma cells. First, we constructed myc-tagged HDGF
expressing vector, and produced stable transformants. HepG2 cells have
a low level of intrinsic HDGF (Fig.
4a). Native HDGF is detected
as a band of about 40 kDa on SDS-PAGE analysis, and a smaller form of
35 kDa is supposed to be a degraded product or post-translationally
modified form. After selection with neomycin, we cloned stable
transformants of HepG2 cells that expressed myc-wHDGF and
myc-HDGFdN1dN2. The expression of these myc-tagged proteins was
confirmed by Western blotting using anti-myc antibody (Fig. 4c). The faint band of about 40 kDa detected by
anti-myc antibody in each lane is a nonspecific band,
because it is also detected in parent and mock cells. As shown in Fig.
5a, myc-wHDGF-expressing HepG2
cells showed a significantly stimulated DNA synthesis that was about
two times greater than the level in neomycin-resistance gene-transfected (neo)-cells in culture medium supplemented with 1%
FCS. On the other hand, myc-HDGFdN1dN2-expressing HepG2 cells did not
show significantly stimulated DNA synthesis greater than neo cells. We
also produced stable myc-wHDGF- and myc-HDGFdN1dN2-expressing NIH3T3
cells (Fig. 4, b and d). myc-wHDGF-expressing
NIH3T3 cells showed significant stimulation of DNA synthesis 2.5 to 3 times greater than that in neo cells in culture medium supplemented with 5% FCS (Fig. 5b). However, myc-HDGFdN1dN2-expressing
NIH3T3 cells showed no stimulated DNA synthesis. Additionally, the
number of myc-wHDGF-expressing HepG2 cells increased significantly from 1.5- to 2-fold that of the parent cells or neo cells after a 4-day culture in medium supplemented with 10% FCS (Fig.
6). However, the increase in the number
of myc-HDGFdN1dN2-expressing HepG2 cells was significantly lower than
that of myc-wHDGF-expressing cells. Thus, the nuclear translocation
potential seems to be essential to the growth-stimulating activity of
HDGF.
Next, we examined DNA synthesis in the bulk of cells expressing
GFP-chimera proteins of HDGF after neomycin selection for about 1 week.
The GFP-protein-expressing 293 cells were microscopically examined for
green fluorescence. As shown in Fig. 7,
GFP-wHDGF-expressing 293 cells showed significantly stimulated DNA
synthesis, about 85% greater than that of 293 cells transfected with
vector only. However, GFP-HDGFdN1dN2-expressing cells and
GFP-HDGFmN1mN2-expressing cells showed significantly diminished
[3H]Thd incorporation to a level almost equal to that of
cells transfected with vector only. GFP-HDGFmN1-expressing cells showed
significantly stimulated DNA synthesis, whereas GFP-HDGFmN2-expressing
cells did not. GFP-HATH-expressing cells did not show significantly stimulated DNA synthesis, although most of the hath protein was translocated to the nucleus (Fig. 7a). Furthermore, we
investigated which part, excluding the hath region, functioned for
growth-stimulating activity, by use of cells expressing GFP-chimera
proteins. Interestingly, GFP-HDGFnonHATH-expressing cells showed
significantly stimulated DNA synthesis, about 120% greater than that
in neo cells, the level of which was almost equal to that of
GFP-wHDGF-expressing cells (Fig. 7). However, neither
GFP-HDGF-LA-expressing cells nor GFP-HDGF-LP-expressing cells showed
significantly stimulated DNA synthesis, although both protein forms
were transported to the nucleus (Fig. 7b). Furthermore,
GFP-HDGF-p53NLS, which was translocated to the nucleus, did not
stimulate DNA synthesis (Fig. 8). These
findings suggest that hath protein alone does not have growth-stimulating activity and gene-specific areas other than the hath
region contribute to the mitogenic activity of HDGF after translocation
to the nucleus.
Exogenously supplied HDGF stimulates the growth of
fibroblasts, endothelial cells, smooth muscle cells, and some hepatoma cells, and is considered to function in these cells as an autocrine or
paracrine factor (1, 3-5). HDGF contains not only a basic amino
acid-rich region (NLS1) in the hath region but also a putative bipartite NLS (NLS2) in a gene-specific area other than the hath region. These experiments using GFP- chimera proteins demonstrated that
HDGF could be translocated into the nucleus via these two NLSs.
NLS2 translocated the truncated forms as well as whole HDGF protein to
the nucleus, in the presence or absence of NLS1. On the other hand,
variable amounts of the hath proteins and NLS2-mutated HDGF proteins
remained in the cytoplasm. Furthermore, the NLS2 peptide translocated
GFP to the nucleus completely, and NLS1 peptide translocated most of
the GFP to the nucleus, although some amount remained in the cytoplasm.
Thus, NLS2 functions as a major NLS signal in the HDGF molecule, and
NLS1 may have the same ability of NLS but functions more weakly as an
assistant for nuclear translocation. A mutated form without basic amino
acids in the NLS sequences (HDGFmN1mN2) as well as NLS-deleted forms
(HDGFdN1dN2, HATHdN1) could not be translocated to the nucleus. Thus,
basic residues in NLSs are essential for the nuclear translocational
potential of NLSs, as reported previously (26-28).
HDGF was detected in the nucleus of endothelial cells and smooth muscle
cells by immunohistochemistry using an anti-C terminus HDGF antibody
(5). We previously reported the cytoplasmic localization of HDGF in
HuH-7 cells, using an anti-N terminus antibody generated in rabbit (1).
Oliver and Al-Awqati (4) also showed a cytoplasmic localization in rat
metanephrogenic mesenchymal cells with no signal in the nucleus, using
immunoaffinity-purified anti-peptide antibody (the peptide used as
antigen had the amino acid sequence of the hath region). One possible
explanation for the difference in these findings is that antibodies
used in the previous reports were generated against the N terminus of
HDGF or the peptide in the hath region, and the antibodies in this
study were generated against the C terminus of HDGF. Some amount of
hath protein was also detected in the cytoplasm in the present study.
These antibodies reacted with the HDGF molecule and with hath protein
cleaved from HDGF, which is probably abundant in the cytoplasm of any
cell type. However, in these previous studies, nuclear staining was not
found. Therefore, either a specific cell type or stage of the cell
cycle might influence the fate of the intracellular localization of
HDGF. Conversely, some amount of imported HDGF in the target cells
might accumulate and remain in the cytoplasm in any cell type, or it
might shuttle between the cytoplasm and the nucleus during cell
differentiation or at different stages of the cell cycle. The high
mobility group-1 protein was reported to be present in both the
cytoplasm and nucleus, and most of it was found in the cytoplasm in
confluent cells whereas it was found in the nucleus in dividing cells
(29). HDGF was co-localized with proliferating cellular nuclear antigen
in the nucleus of proliferating vascular smooth muscle cells (4). It is
reported that another member of the HDGF family, named LEDGF, changed
its intracellular localization from the nucleus to the cytoplasm with
culture temperature (30). Thus, HDGF may shuttle between the cytoplasm
and nucleus as do LEDGF and high mobility group-1, depending on the
phase of the cell cycle, the state of differentiation or the
environmental conditions.
In this study, we showed that the nuclear translocation of HDGF was
essential for its mitogenic activity. Overexpression of the
gene-specific region (HDGFnonHATH) did significantly stimulate DNA
synthesis, almost equal to the effect of wild HDGF, whereas hath
protein could not. HDGFmN1 with intact NLS2 stimulated the DNA
synthesis, suggesting that NLS1 was not essential for the mitogenic
activity. Furthermore, an HDGF mutant containing the NLS sequence of
p53 instead of NLS2, which had nuclear translocation ability, did not
stimulate DNA synthesis, and truncated forms without the C- or
N-terminal side of NLS2 (HDGF-LA and HDGF-LP) did not. We consider that
the mitogenic activity disappeared, because a conformational change
occurred upon replacement of the p53 NLS sequence of the NLS2 locus, or
that the amino acid sequence itself, including NLS2, may be necessary
for the activity, in addition to the ability for nuclear translocation.
These findings suggest that the whole sequence of the gene-specific
region of HDGF, or at least NLS2 and the N- and C-terminal neighboring
portions, is essential for the mitogenic activity.
Recently, it has become evident that some polypeptide factors,
subsequent to receptor-ligand internalization, may translocate to the
nucleus, and that nuclear translocation may be essential for mitogenic
activity. Induction of mitogenesis by FGF is directly dependent on
nuclear localization, whereby the deletion of its NLS abolishes the
mitogenic activity with no effect on other functions (11-13, 31-34).
Additionally, nuclear localization has been reported to be essential
for the mitogenic activity of SDGF, ciliary neurotrophic factor,
amphiregulin, and angiogenin (18-23). The mitogenic activity of HDGF
is dependent on nuclear translocation. Thus, HDGF may belong to a group
of these growth factors that require nuclear translocation to induce
mitogenic activity, at least as one signal pathway. Basic FGF
stimulated cell proliferation and angiogenesis after internalization
and translocation to the nucleus in a receptor-mediated manner (35).
Exogenous acidic FGF was associated with the nucleus in a
receptor-dependent manner, and some cell surface FGF
receptors translocated to a perinuclear location as a functional
tyrosine kinase (36, 37), suggesting that both the tyrosine kinase signal from the activated FGF receptor and growth factor
internalization were required for the induction of cell proliferation
(38). On the other hand, another group asserted that receptor-mediated endocytosis of acidic FGF does not result in its translocation to the
nucleus, because acidic FGF, microinjected into the cytoplasm of baby
hamster kidney cells, enters the cell nucleus by free diffusion and
becomes trapped upon binding to nuclear structures (39). Because the
receptor of HDGF has not yet been identified, it is not clear whether
nuclear translocation is essential for the receptor-mediated signal
transduction as seen in basic FGF and SDGF. However, it is notable that
green fluorescence was detected in the nucleus 72 h after the
extracellular addition of GFP-HDGF, suggesting that exogenously
supplied HDGF was truly internalized. Furthermore, GFP-HATH protein was
internalized, but GFP-HDGF-LP or GFP-HDGFnonHATH was not. Although the
time until visualization, 72 h, seems to be longer for DNA
synthesis, we consider that the accumulation of sufficient amounts of
GFP proteins must be necessary to detect the fluorescence. These
findings suggest that exogenously supplied HDGF is internalized into
the cytoplasm, probably after binding to the cell membrane (possible
receptor) via the hath region, and then is transported to the nucleus
via NLS in the HDGF molecule.
The growth-stimulating behavior of the stable transformants
overexpressing the growth factor lacking a signal peptide may be
explained by the prediction that HDGF is largely sequestered in a
cellular compartment different from that of its receptor. Non-secreted
acidic FGF, lacking the secretion signal, functions in cell
motility and invasive potential compared with the secreted form of
acidic FGF encoding cDNA coupled to a signal peptide sequence, indicating its ability for intracellular signaling in a so-called intracrine manner (40). Our current findings demonstrating that the HDGF-producing cells have growth-stimulating activity after nuclear
translocation may support the functional intracrine signaling of HDGF.
HRP-1 and HRP-3 were detected in the nucleus by immunohistochemistry and GFP-tagged fluorescence microscopy (6, 7). Another member of the
HDGF family, HRP-2, had a higher molecular weight than other HDGF
proteins and was a more basic protein containing many Lys and Arg amino
acids in a gene-specific region, strongly suggesting that it might be a
transcriptional regulatory protein (2). p52/p75 were cloned first as
transcriptional coactivators; however, they contain the hath region in
the N-terminal sequence and, therefore, must belong to the HDGF family
(41). Interestingly, p75 (which we would like to call HRP-5) was
reported to be a survival and growth factor for lens epithelial cells,
fibroblasts, and keratinocytes (23). Synthetic peptides containing the
NLS of acidic FGF were able to stimulate DNA synthesis in an FGF
receptor-independent manner after delivery into living NIH3T3 cells by
a cell-permeable peptide import technique, suggesting that exogenous
FGF was internalized and directly involved in the nuclear transport
(31). Furthermore, basic FGF stimulated gene transcription in a
cell-free system, suggesting a direct function in nuclear events (16).
FGF-2 activated ribosomal DNA transcription and showed a strong
affinity for histone H1. FGF-2 regulated gene expression through
modulation of chromatin structure in the nucleus (42). In our study,
HDGFnonHATH-overexpressing cells showed increased DNA synthesis,
suggesting that HDGFnonHATH was transported to the nucleus directly and
stimulated DNA synthesis. It may be postulated that HDGF translocates
to the nucleus directly and regulates gene expression. Therefore, HDGF
may function in an intracrine fashion for cell proliferation as well as
having autocrine or paracrine functions, or it might function as a
transcriptional regulatory protein after direct translocation to the
nucleus in any cell type.
HDGF has no signal peptide, but some amount of HDGF was detected in the
conditioned medium of HuH-7 cells, HepG2 cells, and COS cells
overexpressing HDGF (1). Some growth factors were reported to have no
signal peptides, such as FGF-1, -2, -9, and -11 through -14 and
interleukin-1 (43-46). It is reasonable to consider that the HDGF
protein in the conditioned medium is released from lysed or dead cells,
although we cannot exclude the possibility that HDGF is secreted via an
internal hydrophobic sequence as an internal signal sequence (1) or by
a non-classic secretory pathway. Most of the HDGF present
extracellularly must be a consequence of cell lysis and would not be
physiological. However, we consider these factors to have possible
roles under pathogenic conditions. For example, when the tissue was
damaged and cells were destroyed by mechanical stress or inflammation,
growth factors such as HDGF in the cytoplasm and/or nucleus were
released, and these could act on adjacent progenitor cells and
stimulate cell proliferation to repair the tissue. In any cell type,
these non-receptor-mediated signals may induce cell proliferation or
survival after direct translocation to the nucleus. These pathways
might work for some factors as a primitive signal pathway in biological
functions for cell survival and repair.
In summary, HDGF translocates to the nucleus via nuclear localization
signals, mainly NLS2, in a gene-specific region as the major potential
NLS, and NLS1 in the hath region may be an assistant. The nuclear
translocation is essential for the mitogenic activity of HDGF.
Exogenously supplied GFP-HDGF is undoubtedly internalized and
translocated to the nucleus, although its receptor has not yet been
identified. HDGF is supposed to be internalized into the cytoplasm
after binding to a possible membrane receptor in the hath region and
then translocated to the nucleus via mainly NLS in a gene-specific part
other than the hath region. The gene-specific region, or at least NLS2
and the N- and C-terminal neighboring portions, may contribute to
mitogenic activity in the HDGF molecule. HDGF (and other members of the
HDGF family) may function as nuclear/growth factors in an autocrine,
paracrine, and/or intracrine manner.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

View larger version (23K):
[in a new window]
Fig. 1.
Plasmid construction of truncated and mutant
forms of HDGF. The shaded boxes show the NLS1 or NLS2
with mutated amino acids, and the mark
shows the deletions in NLSs,
as described under "Materials and Methods."
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

View larger version (20K):
[in a new window]
Fig. 2.
Two nuclear localization signals
function in the HDGF molecule. 293 cells were transiently
transfected with pEGFP-C1 containing cDNA of wild type, truncated,
or mutant forms of HDGF. The living 293 cells transfected with pEGFP-C1
were evaluated on day 3 using confocal microscopy equipped for GFP
visualization (488-nm excitation and FITC filter set). The photographs
show 293 cells expressing: a, mock, transfected with pEGF-C1
vector; b, GFP-wHDGF; c, GFP-HATH; d,
GFP-HDGFnonHATH; e, GFP-HDGFmN1; f, GFP-HDGFmN2;
g, GFP-HDGFmN1mN2; h, GFP-HDGFdN1dN2;
i, GFP-HDGF-LA; j, GFP-HDGF-SA; k,
GFP-HDGF-LP; l, GFP-HDGF-SP; m, GFP-HATHmN1;
n, GFP-HATHdN1; o, GFP-NLS1+; p,
GFP-NLS2.

View larger version (124K):
[in a new window]
Fig. 3.
Exogenously added GFP-HDGF accumulates in the
nucleus of target cells. The conditioned media of 293 cells
expressing GFP-chimera proteins of HDGF, HDGFdN1dN2, and HATH were
concentrated about 20-fold by Centricon10 and then added to parent 293 cells extracellularly. Three days later, we evaluated the intracellular
fluorescence by microscopy equipped for GFP visualization. The
photographs show the 293 cells supplied exogenously: a,
GFP-wHDGF; b, GFP-HDGFdN1dN2; c, GFP-HATH; and
d, GFP-HDGFnonHATH.

View larger version (46K):
[in a new window]
Fig. 4.
Overexpression of myc-tagged HDGF proteins in
stable transformants. The protein levels of wild type and mutant
forms of HDGF expressed in stable transformants were evaluated by
Western blotting. Myc-tagged wild HDGF was highly expressed in HepG2
cells and NIH3T3 cells relative to intrinsic HDGF in their
neomycin-selected and parent cells, using an anti-C terminus HDGF
polyclonal antibody. Myc-tagged HDGF and its mutant forms in stable
transformants of HepG2 cells (a, b) and NIH3T3
cells (c, d) were detected with an anti-C
terminus HDGF polyclonal antibody at a dilution of 1000-fold
(a, c) or anti-myc monoclonal antibody at a
dilution of 10-fold (b, d). In a and
b: lane 1, parent HepG2; lanes 2 and
3, mock clones 1 and 2; lanes 4 and 5,
clones 1 and 2 expressing myc-HDGFdN1dN2; lanes 6 and
7, clones 1 and 2 expressing myc-wHDGF. In c and
d: lane 1, parent NIH3T3; lanes 2 and
3, mock clones 1 and 2; lanes 4 and 5,
clones 1 and 2 expressing myc-HDGFdN1dN2; lanes 6 and
7, clones 1 and 2 expressing myc-wHDGF. Each
arrow shows a protein band corresponding to intrinsic HDGF
(I), myc-tagged wild type, or mutant HDGF
(M).

View larger version (37K):
[in a new window]
Fig. 5.
HepG2 and NIH3T3 cells overexpressing wild
type HDGF stimulate DNA synthesis, but cells overexpressing mutant
forms of HDGF without NLSs do not. HepG2 cells were cultured in
DMEM supplemented with 1% FCS for 96 h and then
harvested for DNA synthesis. NIH3T3 cells were cultured in
DMEM supplemented with 5% FCS for 48 h and then
harvested. In a: HepG2 cells. Lanes 1 and
2, mock clones 1 and 2; lanes 3 and 4,
clones 1 and 2 expressing myc-HDGFdN1dN2; lanes 5 and
6, clones 1 and 2 expressing myc-wHDGF. In b:
NIH3T3 cells. Lanes 1 and 2, mock clones 1 and 2;
lanes 3 and 4, clones 1 and 2 expressing
myc-HDGFdN1dN2; lanes 5 and 6, clones 1 and 2 expressing myc-wHDGF. *, p < 0.05 versus
mock clones and myc-HDGFdN1dN2-expressing cells.

View larger version (17K):
[in a new window]
Fig. 6.
HepG2 cells overexpressing wild type HDGF
stimulate cell proliferation, but cells overexpressing mutant forms of
HDGF without NLSs do not. HepG2 cells were cultured in
DMEM supplemented with 10% FCS, and 2 and 4 days later
cell numbers were determined by the MTS method. Open and
closed squares, mock clones 1 and 2; open and
closed triangles, clones 1 and 2 expressing myc-HDGFdN1dN2;
open and closed circles, clones 1 and 2 expressing myc-wHDGF. *, p < 0.05 versus
mock clones and myc-HDGFdN1dN2-expressing cells.

View larger version (39K):
[in a new window]
Fig. 7.
Increased DNA synthesis in 293cells
expressing GFP-wHDGF or GFP-HDGFnonHATH but not in cells
expressing GFP-HDGF without NLSs or GFP-HATH. 293 cells
expressing GFP-chimera proteins of wild type HDGF, its mutant, or
truncated forms were cultured in DMEM supplemented with1%
FCS and were harvested 4 days later. In a: lane
1, mock, transfected with pEGFP-C1 vector; lane 2,
GFP-HDGFmN1mN2; lane 3, GFP-HDGFdN1dN2; lane 4,
GFP-HDGFmN1; lane 5, GFP-HDGFmN2; lane 6,
GFP-HATH; lane 7, GFP-HDGFnonHATH; lane 8,
GFP-wHDGF. In b: lane 1, mock; lane 2,
GFP-HATH; lane 3, GFP-HDGFnonHATH; lane 4,
GFP-HDGF-SA; lane 5, GFP-HDGF-LA; lane 6,
GFP-HDGF-LP. *, p < 0.05 versus mock,
GFP-HDGFmN1mN2, GFP-HDGFdN1dN2, and GFP-HATH; **, p < 0.001 versus mock, GFP-HATH, GFP-HDGF-SA, GFP-HDGF-LA,
and GFP-HDGF-LP.

View larger version (17K):
[in a new window]
Fig. 8.
HDGF containing the NLS sequence of p53
instead of NLS2 cannot stimulate DNA synthesis. a,
microscopy of 293 cells expressing GFP-HDGF-p53NLS. The living 293 cells transfected with pEGFP-C1 containing HDGF-p53NLS were evaluated
on day 3 using confocal microscopy equipped for GFP visualization
(488-nm excitation and FITC filter set). b, DNA synthesis in
293 cells. 293 cells expressing GFP-HDGF-p53NLS were cultured in
DMEM supplemented with 1% FCS, and were harvested 4 days
later. Lane 1, mock; lane 2, GFP-HDGF-p53NLS;
lane 3, GFP-wHDGF. *, p < 0.005 versus mock, GFP-HDGF-p53NLS.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
| |
FOOTNOTES |
|---|
* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed. Tel.: 81-6-6879-3837; Fax: 81-6-6879-3839; E-mail: nakamura@imed3.med.osaka-u. ac.jp.
Published, JBC Papers in Press, December 18, 2001, DOI 10.1074/jbc.M111122200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: HDGF, hepatoma-derived growth factor; NLS, nuclear localization signal; HRP, HDGF-related protein; FGF, fibroblast growth factor; SDGF, schwannoma-derived growth factor; LEDGF, lens epithelium-derived growth factor; GFP, green fluorescence protein; DMEM, Dulbecco's modified Eagle's medium; FCS, fetal calf serum; FITC, fluorescein isothiocyanate; Thd, thymidine; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Nakamura, H.,
Izumoto, Y.,
Kambe, H.,
Kuroda, T.,
Mori, T.,
Kawamura, K.,
Yamamoto, H.,
and Kishimoto, T.
(1994)
J. Biol. Chem.
269,
25143-25149 |
| 2. |
Izumoto, Y.,
Kuroda, T.,
Harada, H.,
Kishimoto, T.,
and Nakamura, H.
(1997)
Biochem. Biophys. Res. Commun.
238,
26-32[CrossRef][Medline]
[Order article via Infotrieve] |
| 3. |
Nakamura, H.,
Kambe, H.,
Egawa, T.,
Kimura, Y.,
Ito, H.,
Hayashi, E.,
Yamamoto, H.,
Sato, J.,
and Kishimoto, S.
(1989)
Clin. Chim. Acta
183,
273-284[CrossRef][Medline]
[Order article via Infotrieve] |
| 4. |
Oliver, J. A.,
and Al-Awqati, Q.
(1998)
J. Clin. Invest.
102,
1208-1219[Medline]
[Order article via Infotrieve] |
| 5. |
Everett, A. D.,
Lobe, D. R.,
Matsumura, M. E.,
Nakamura, H.,
and McNamara, C. A.
(2000)
J. Clin. Invest.
105,
567-575[Medline]
[Order article via Infotrieve] |
| 6. |
Kuroda, T.,
Tanaka, H.,
Nakamura, H.,
Nishimune, Y.,
and Kishimoto, T.
(1999)
Biochem. Biophys. Res. Commun.
262,
433-437[CrossRef][Medline]
[Order article via Infotrieve] |
| 7. |
Ikegame, K.,
Yamamoto, M.,
Kuroda, T.,
Kishima, Y.,
Enomoto, H.,
Yoshida, K.,
Suemura, M.,
Kishimoto, T.,
and Nakamura, H.
(1999)
Biochem. Biophys. Res. Commun.
266,
81-87[CrossRef][Medline]
[Order article via Infotrieve] |
| 8. |
Jans, D. A.
(1994)
FASEB J.
8,
841-847[Abstract] |
| 9. |
Prochiantz, A.,
and Theodore, L.
(1995)
Bioessays
17,
39-44[CrossRef][Medline]
[Order article via Infotrieve] |
| 10. |
Jans, D. A.,
and Hassan, G.
(1998)
Bioessays
20,
400-411[CrossRef][Medline]
[Order article via Infotrieve] |
| 11. |
Imamura, T.,
Engleka, K.,
Zhan, X.,
Tokita, Y.,
Forough, R.,
Roeder, D.,
Jackson, A.,
Maier, J. A.,
Hla, T.,
and Maciag, T.
(1990)
Science
249,
1567-1570 |
| 12. |
Imamura, T.,
Tokita, Y.,
and Mitsui, Y.
(1992)
J. Biol. Chem.
267,
5676-5679 |
| 13. |
Wiedlocha, A.,
Falnes, P. O.,
Madshus, I. H.,
Sandvig, K.,
and Olsnes, S.
(1994)
Cell
76,
1039-1051[CrossRef][Medline]
[Order article via Infotrieve] |
| 14. |
Baldin, V.,
Roman, A. M.,
Bosc-Bierne, I.,
Amalric, F.,
and Bouche, G.
(1990)
EMBO J.
9,
1511-1517[Medline]
[Order article via Infotrieve] |
| 15. |
Amalric, F.,
Baldin, V.,
Bosc-Bierne, I.,
Couderc, B.,
Guyader, M.,
Patry, V.,
Prats, H.,
Roman, A. M.,
and Bouche, G.
(1991)
Ann. N. Y. Acad. Sci.
638,
127-138[Medline]
[Order article via Infotrieve] |
| 16. |
Nakanishi, Y.,
Kihara, K.,
Mizuno, K.,
Masamune, Y.,
Yoshitake, Y.,
and Nishikawa, K.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
5216-5220 |
| 17. |
Antoine, M.,
Reimers, K.,
Dickson, C.,
and Kiefer, P.
(1997)
J. Biol. Chem.
272,
29475-29481 |
| 18. |
Kimura, H.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
2165-2169 |
| 19. |
Bajetto, A.,
Schettini, G.,
and Chimini, G.
(1999)
Brain Res.
818,
565-569[CrossRef][Medline]
[Order article via Infotrieve] |
| 20. |
Johnson, G. R.,
Saeki, T.,
Auersperg, N.,
Gordon, A. W.,
Shoyab, M.,
Salomon, D. S.,
and Stromberg, K.
(1991)
Biochem. Biophys. Res. Commun.
180,
481-488[CrossRef][Medline]
[Order article via Infotrieve] |
| 21. |
Johnson, G. R.,
Saeki, T.,
Gordon, A. W.,
Shoyab, M.,
Salomon, D. S.,
and Stromberg, K.
(1992)
J. Cell Biol.
118,
741-751 |
| 22. |
Moroianu, J.,
and Riordan, J. F.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
1677-1681 |
| 23. |
Singh, D. P.,
Ohguro, N.,
Kikuchi, T.,
Sueno, T.,
Reddy, V. N.,
Yuge, K.,
Chylack, L. T., Jr.,
and Shinohara, T.
(2000)
Biochem. Biophys. Res. Commun.
267,
373-381[CrossRef][Medline]
[Order article via Infotrieve] |
| 24. |
Addison, C.,
Jenkins, J.,
and Sturzbecher, H. W.
(1990)
Oncogene
5,
423-426[Medline]
[Order article via Infotrieve] |
| 25. |
Mizushima, S.,
and Nagata, S.
(1990)
Nucleic Acids Res.
18,
5322-5323 |
| 26. |
Robbins, J.,
Dilworth, S. M.,
Laskey, R. A.,
and Dingwall, C.
(1991)
Cell
64,
615-623[CrossRef][Medline]
[Order article via Infotrieve] |
| 27. |
Zacksenhaus, E.,
Bremner, R.,
Phillips, R. A.,
and Gallie, B. L.
(1993)
Mol. Cell. Biol.
13,
4588-4599 |
| 28. |
Makkerh, J. P. S.,
Dingwall, C.,
and Laskey, R. A.
(1996)
Curr. Biol.
6,
1025-1027[CrossRef][Medline]
[Order article via Infotrieve] |
| 29. |
Mosevitsky, M.,
Novitskaya, V. A.,
Iogannsen, M. G.,
and Zabezhinsky, M. A.
(1989)
Eur. J. Biochem.
185,
303-310[Medline]
[Order article via Infotrieve] |
| 30. |
Singh, D. P.,
Ohguro, N.,
Chylack, L. T., Jr.,
and Shinohara, T.
(1999)
Invest. Ophthalmol. Vis. Sci.
40,
1444-1451 |
| 31. |
Lin, Y.-Z.,
Yao, S. Y.,
and Hawiger, J.
(1996)
J. Biol. Chem.
271,
5305-5308 |
| 32. |
Klingenberg, O.,
Wiedlocha, A.,
Rapak, A.,
Munoz, R.,
Falnes, P.,
and Olsnes, S.
(1998)
J. Biol. Chem.
273,
11164-11172 |
| 33. |
Mehta, V. B.,
Connors, l.,
Wang, H.-C. R.,
and Chiu, I.-M.
(1998)
J. Biol. Chem.
273,
4197-4205 |
| 34. |
Bailly, K.,
Soulet, F.,
Leroy, D.,
Almaric, F.,
and Bouche, G.
(2000)
FASEB J.
14,
333-344 |
| 35. |
Hawker, J. R., Jr.,
and Granger, H. J.
(1992)
Am. J. Physiol.
262,
1527-1537 |
| 36. |
Zhan, X., Hu, X.,
Friesel, R.,
and Maciag, T.
(1993)
J. Biol. Chem.
268,
9611-9620 |
| 37. |
Prudovsky, I.,
Savion, N.,
Zhan, X.,
Friesel, R., Xu, J.,
Hou, J.,
McKeehan, W. L.,
and Maciag, T.
(1994)
J. Biol. Chem.
269,
31720-31724 |
| 38. |
Wiedlocha, A.,
Falnes, P. O.,
Rapak, A.,
Munoz, R.,
Klingenberg, O.,
and Olsnes, S.
(1996)
Mol. Cell. Biol.
16,
270-280[Abstract] |
| 39. |
Cao, Y.,
Ekstrom, M.,
and Pettersson, R. F.
(1993)
J. Cell Sci.
104,
77-87[Abstract] |
| 40. |
Jouanneau, J.,
Gavrilovic, J.,
Caruelle, D.,
Jaye, M.,
Moens, G.,
Caruelle, J. P.,
and Thiery, J. P.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
2893-2897 |
| 41. |
Ge, H., Si, Y.,
and Roeder, R. G.
(1998)
EMBO J.
17,
6723-6729[CrossRef][Medline]
[Order article via Infotrieve] |
| 42. |
Almaric, F.,
Bouche, G.,
Bonnet, H.,
Brethenou, P.,
Roman, A. M.,
Truchet, I.,
and Quarto, N.
(1994)
Biochem. Pharmacol.
47,
111-115[CrossRef][Medline]
[Order article via Infotrieve] |
| 43. |
March, C. J.,
Mosley, B.,
Larsen, A.,
Cerreti, D. P.,
Braedt, G.,
Price, V.,
Gillis, S.,
Henney, C. S,
and Kronheim, S. R.
(1985)
Nature
315,
641-647[CrossRef][Medline]
[Order article via Infotrieve] |
| 44. |
Burgess, W. H.,
and Maciag, T.
(1989)
Ann. Rev. Biochem.
58,
575-606[CrossRef][Medline]
[Order article via Infotrieve] |
| 45. |
Ornits, D. M.,
and Itoh, N.
(2001)
Genome Biol.
2,
3005.1-3005.12 |
| 46. |
Munoz-Sanjuan, I.,
Smallwood, P. M.,
and Nathans, J.
(2000)
J. Biol. Chem.
275,
2589-2597 |
This article has been cited by other articles:
![]() |
S. Yamamoto, Y. Tomita, Y. Hoshida, E. Morii, T. Yasuda, Y. Doki, K. Aozasa, H. Uyama, H. Nakamura, and M. Monden Expression Level of Hepatoma-Derived Growth Factor Correlates with Tumor Recurrence of Esophageal Carcinoma Ann. Surg. Oncol., July 1, 2007; 14(7): 2141 - 2149. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Uyama, Y. Tomita, H. Nakamura, S. Nakamori, B. Zhang, Y. Hoshida, H. Enomoto, Y. Okuda, M. Sakon, K. Aozasa, et al. Hepatoma-Derived Growth Factor Is a Novel Prognostic Factor for Patients with Pancreatic Cancer. Clin. Cancer Res., October 15, 2006; 12(20): 6043 - 6048. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. V. Tkatchenko, P. A. Walsh, T. V. Tkatchenko, S. Gustincich, and E. Raviola Form deprivation modulates retinal neurogenesis in primate experimental myopia PNAS, March 21, 2006; 103(12): 4681 - 4686. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Yoshida, Y. Tomita, Y. Okuda, S. Yamamoto, H. Enomoto, H. Uyama, H. Ito, Y. Hoshida, K. Aozasa, H. Nagano, et al. Hepatoma-Derived Growth Factor Is a Novel Prognostic Factor for Hepatocellular Carcinoma Ann. Surg. Oncol., February 1, 2006; 13(2): 159 - 167. [Abstract] [Full Text] [PDF] |
||||